Stock Price Quote

NATCO PHARMA LTD.

NSE : NATCOPHARMBSE : 524816ISIN CODE : INE987B01026Industry : Pharmaceuticals & DrugsHouse : Natco
BSE1174.552.6 (+0.22 %)
PREV CLOSE ( ) 1171.95
OPEN PRICE ( ) 1186.25
BID PRICE (QTY) 1174.50 (6)
OFFER PRICE (QTY) 1175.15 (84)
VOLUME 28669
TODAY'S LOW / HIGH ( )1167.55 1191.15
52 WK LOW / HIGH ( )621.1 1259.45
NSE1171.15-1.3 (-0.11 %)
PREV CLOSE( ) 1172.45
OPEN PRICE ( ) 1177.20
BID PRICE (QTY) 1171.20 (55)
OFFER PRICE (QTY) 1171.95 (5)
VOLUME 550254
TODAY'S LOW / HIGH( ) 1168.55 1192.15
52 WK LOW / HIGH ( )621 1259.45
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 19-09 1981
Management Info
G S Murthy - Chairman V C Nannapaneni - Managing Director
Registered Office

Address Natco House,Road No 2,Banjara Hills,
Hyderabad,
Telangana-500034

Phone 040-23547532

Email investors@natcopharma.co.in / dasaradhi@natcopharma.co.in

Website www.natcopharma.co.in

Registrars Details
Venture Capital & Corporate Investments Ltd
Aurum, Door No 4-50/P-II/57/4F&5F Plot No 57,4th & 5th Floors,Jayabheri Enclave Phase - II, Gachibowli,Hyderabad
Listing : BSE, NSE, MCX

NEWS

28May Natco Pharma informs about press release
Natco Pharma has informed that it enclosed Copy of News Paper Publicatio..
15May NATCO Pharma informs about earnings call
NATCO Pharma has informed that the Company will host an Earnings Call wi..
14May Natco Pharma informs about details of
Natco Pharma has informed that they are in process of issuing duplicate..
23Apr NATCO Pharma informs about disclosure
Further to its earlier intimation dated November 2, 2023 about the succe..
18Apr NATCO Pharma informs about press release
NATCO Pharma has informed that it enclosed the Press Release and disclos..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit349113066
Gross Profit 4325 15553
Operating Profit 488617417
Net Sales 964835689

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  6555.50 (0.98%)
M.Cap ( in Cr)8420.45
Fredun Pharma (BSE)
peergroup  925.00 (5.61%)
M.Cap ( in Cr)405.09
Shilpa Medicare (BSE)
peergroup  570.05 (8.03%)
M.Cap ( in Cr)5518.83
Divi's Lab (BSE)
peergroup  4505.00 (0.61%)
M.Cap ( in Cr)118717.55
Solara Active Pharma (BSE)
peergroup  444.10 (5.81%)
M.Cap ( in Cr)2121.78

Shareholding Pattern

FI/BANKS/INSURANCE 5.58%
PROMOTERS 49.71%
MUTUAL FUNDS/UTI 4.08%
NON-INSTITUTION 24.46%
GOVERNMENT 0%
FII 0%

About Natco Pharma Ltd.

Natco Pharma Ltd. was incorporated in the year 1981. Its today's share price is 1174.55. Its current market capitalisation stands at Rs 21028.39 Cr. In the latest quarter, company has reported Gross Sales of Rs. 23976 Cr and Total Income of Rs.24604 Cr. The company's management includes Vijayabhaskar Dronadula, Agnihotra Dakshina Murty Chavali, Venkat Ramesh Chekuri, Pavan Ganapati Bhat, D Linga Rao, MUR Naidu, PSRK Prasad, Rajeev Nannapaneni, D G Prasad, Leela Digumarti, TV Rao, G S Murthy, V C Nannapaneni.

It is listed on the BSE with a BSE Code of 524816 , NSE with an NSE Symbol of NATCOPHARM and ISIN of INE987B01026. It's Registered office is at Natco House,Road No 2,Banjara HillsHyderabad-500034, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Brahmayya & Co, BSR & Associates LLP, Walker Chandiok & Co LLP, Walker, Chandiok & Co, Walker, Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.